| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Spike protein of SARS-CoV-2 |
| Clinical data | |
| Trade names | Pemgarda |
| Other names | VYD222 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Pemivibart, sold under the brand name Pemgarda, is a monoclonal antibody medication authorized for the pre-exposure prophylaxis (prevention) of COVID‑19.[4] Pemivibart was developed by Invivyd.[3][5]
The US Food and Drug Administration (FDA) issued an emergency use authorization for pemivibart in March 2024.[4][5]
- ^ "Pemgarda- pemivibart injection". DailyMed. 22 March 2024. Retrieved 17 October 2024.
- ^ "Emergency Use Authorization: Pemgarda (pemivibart)". U.S. Food and Drug Administration (FDA). 22 March 2024.
- ^ a b "Highlight of Emergency Use Authorization: Pemgarda (pemivibart)". U.S. Food and Drug Administration (FDA). Archived from the original on 23 March 2024. Retrieved 23 March 2024.
- ^ a b "FDA Roundup: March 22, 2024". U.S. Food and Drug Administration (FDA). 22 March 2024. Archived from the original on 23 March 2024. Retrieved 23 March 2024.
This article incorporates text from this source, which is in the public domain.
- ^ a b "Invivyd Announces FDA Authorization for Emergency Use of Pemgarda (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19" (Press release). Invivyd. 22 March 2024. Archived from the original on 23 March 2024. Retrieved 23 March 2024 – via GlobeNewswire.
